Physician profile
Robert E Holladay
NPI 1689660615
$1,831.92
in general payments reported to CMS, 2019-2025
13 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.79 · 2020: $25.05 · 2021: $60.86 · 2022: $106 · 2023: $48.09 · 2024: $262 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,076 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,076.38 |
| Food and Beverage | $484.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,076.38 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.75 | 2024 | Ofev |
| Electromed, INC. | $113.80 | 2023-2025 | Smartvest |
| Astrazeneca Pharmaceuticals Lp | $106.00 | 2022 | |
| Pfizer INC. | $103.84 | 2019-2020 | |
| Genentech USA, INC. | $82.62 | 2023-2025 | Xolair, Tecentriq, Phesgo |
| Inspire Medical Systems, INC. | $57.97 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $47.95 | 2021 | |
| Verona Pharma, INC. | $28.80 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $25.63 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2024 | Takhzyro |
| Pharmacosmos Therapeutics INC. | $14.35 | 2025 | Monoferric |
| Novo Nordisk INC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holladay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.